Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
US10208124B2 · kind B2 · utility
4Cited by
2References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 2, 2015 |
| Grant date | Feb 19, 2019 |
| Priority date | — |
| Expiry date | Jul 23, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.